Quark Biotech, Inc.

Description

Quark is a privately held company incorporated in California. Our headquarters is located at 6501 Dumbarton Circle, Fremont, CA 94555, USA, and we have R&D facilities at 2990 Wilderness Place, in Boulder Colorado 80301 and at QBI Enterprises, Ltd. in Nes Ziona, Israel. QBI Enterprises, Ltd. is a wholly owned subsidiary of Quark Pharmaceuticals, Inc.

“We are very pleased to collaborate with Biocon Limited, a pioneer in biopharmaceuticals. It is the only Indian company to develop several difficult to make biologics and biosimilars and has provided affordable healthcare solutions for the patients in India and other markets. We believe siRNA is going to make a very important impact in the field of pharmaceuticals discovery and development.

In August 2010, Quark granted Novartis an option for an exclusive worldwide license to develop and commercialize QPI-1002 and any other p53-directed siRNAs controlled by Quark for any indication. Under the agreement, Novartis paid Quark a non-refundable option grant fee and has the right to exercise the option during or following the Phase II trials of QPI-1002. Quark is fully responsible for conducting these Phase II clinical trials.

Quark is a clinical stage pharmaceutical company focusing on the development of RNAi-based therapeutics. We have a fully integrated Research and Development team with a proven track record of translating our innovations in RNAi therapeutics from the bench to the clinic. Our Discovery group is located in the Weizmann Science Park in Israel as part of QBI Enterprises, a wholly owned subsidiary of Quark Pharmaceuticals.

Founded in December 1994, Quark devoted its early years to developing its proprietary technology platform, “BiFAR™”, to identify novel drug targets. BiFAR™ combines high throughput gene inhibition technology with microarray expression profiling to identify genes responsible for disease processes. In collaboration with large pharmaceutical partners, we applied our BiFAR™ platform to identify new therapeutic targets in serious diseases with unmet medical needs. Today we are harvesting the fruits of the innovative targets we identified and the corresponding therapeutic concepts.

Companies nearby